ROLE OF IMMUNOSUPPRESSANTS IN COVID PATIENTS

Vinaya V. Jadhav; Irshad A. Shaikh; Shyamlila B. Bavage; Nandkishor B. Bavage

ROLE OF IMMUNOSUPPRESSANTS IN COVID PATIENTS

Authors: Vinaya V. Jadhav, Irshad A. Shaikh, Shyamlila B. Bavage, Nandkishor B. Bavage

Unique Paper ID: 152373
Volume: 8
Issue: 3
PageNo: 143-150

Keywords: Covid-19 SARS-CoV-2 coronavirus immunosuppressive drugs corticosteroid mycophenolic acid calcineurin inhibitors.

Abstract:
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 in Wuhan city, Hubei province, China. This is the third and largest coronavirus outbreak since the new millennium after SARS in 2002 and Middle East respiratory syndrome (MERS) in 2012. Over 3â€‰million people have been infected and the COVID-19 has caused more than 217 000 deaths. A concern exists regarding the vulnerability of patients who have been treated with immunosuppressive drugs prior or during this pandemic. Would they be more susceptible to infection by the SARS-CoV-2 and how would their clinical course be altered by their immunosuppressed state? This is a question the wider medical fraternityâ€”including ophthalmologists, rheumatologists, gastroenterologist and transplant physicians among othersâ€”must answer. The evidence from the SARS and MERS outbreak offer some degree of confidence that immunosuppression is largely safe in the current COVID-19 pandemic. Preliminary clinical experiences based on case reports, small series and observational studies show the morbidity and mortality rates in immunosuppressed patients may not differ largely from the general population. Overwhelmingly, current best practice guidelines worldwide recommended the continuation of immunosuppression treatment in patients who require them except for perhaps high-dose corticosteroid therapy and in patients with associated risk factors for severe COVID-19 disease.

Download article

email to a friend

Cite This Article

ISSN: 2349-6002
Volume: 8
Issue: 3
PageNo: 143-150

ROLE OF IMMUNOSUPPRESSANTS IN COVID PATIENTS

Available:https://ijirt.org/Article?manuscript=152373

09 Nov, 2021

REVIEW ON DIABETES MELLITUS

17 Oct, 2021

DRUG REPURPOSING IN ANTIVIRAL RESEARCH: A REVIEW

08 Aug, 2021

RHINO-ORBITAL MUCORMYCOSIS ASSOCIATED WITH COVID-19

08 Aug, 2021

THE PRINCIPLES OF SKIN TISSUE ENGINEERING

08 Aug, 2021

A REVIEW ON LYME BORRELIOSIS

31 Jul, 2021

AWARENESS ABOUT BANNED DRUG

31 Jul, 2021

APPLICATION AND THE PRODUCTION OF RADIOPHARMACEUTICAL’S

30 Jul, 2021

ANTHELMINTIC ACTIVITY OF SOME MEDICINAL PLANTS

30 Jul, 2021

A REVIEW ON DRUMSTICK PLANTS (MORINGA OLEIFERA) MEDICAL USES AND NUTRITIONAL PROPERTIES

29 Jul, 2021

PHARMACOTHERAY OF HYPERTENSION

Impact Factor
8.01 (Year 2024)

UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry